Legionnaires' disease is a form of atypical pneumonia caused by bacteria of the genus *Legionella*. *L. pneumophila* serogroup 1 causes most Legionnaires' disease ([@R1]). Although Legionnaires' disease has been reported worldwide, only a few sporadic cases have been reported in China ([@R2]). Investigation of *Legionella* infection is urgently needed in China to describe its prevalence and epidemiology.

During 2014--2016, we conducted surveillance of Legionnaires' disease in 18 hospitals in China under the coordination of the Chinese Center for Disease Control and Prevention (China CDC). The Ethical Committee of the National Institute for Communicable Disease Control and Prevention, China CDC (ICDC-2014009), provided ethics approval for this study. The distribution of the 18 hospitals accounted for all regions of China ([Appendix](#SD1){ref-type="local-data"} Figure 1). The hospital\'s clinical diagnostic level, pneumonia pathogen detection level, and degree of cooperation with this investigation were also considered. All 18 hospitals are level 3 first-class general hospitals, representing the highest level of healthcare in their cities.

The 3,132 severe pneumonia cases were defined and detected according to the Guidelines for the Diagnosis and Treatment of Community-Acquired Pneumonia in Adults in China (2016 edition) ([@R3]) ([Appendix](#SD1){ref-type="local-data"} Figure 2). Among them, 1,885 cases were diagnosed as noninfectious or nonbacterial infections, and 771 cases were diagnosed as bacterial infections other than *Legionella* by daily testing, including bacterial culture, viral nucleic acid detection, and immunologic detection in hospital laboratories. Patients with the remaining 476 cases of pneumonia with unknown cause were enrolled and tested for *Legionella* infection. Among them, 190 left the hospital, died, or were unwilling to cooperate. Thus, urine samples were collected from 286 patients and sent for urine antigen detection for *L. pneumophila* serogroup 1 (BinaxNow, <https://www.alere.com>) ([Appendix](#SD1){ref-type="local-data"} Figure 2). Sputum samples were obtained from 211 of the 286 patients and sent to the laboratory of China CDC (Beijing, China) for *Legionella* culture, which used both buffered charcoal yeast extract agar and buffered charcoal yeast extract agar supplemented with *Legionella* GVPC (glycine, vancomycin, polymyxin, cycloheximide) Selective Supplement (Oxoid, [https://www.thermofisher.com](https://www.thermofisher.com/)). Eleven (3.85%) of the 286 urine samples yielded positive results, and we isolated *Legionella* strains from 7 of them. All 7 *L. pneumophila* cultures were obtained from the same patients who tested positive by urine antigen detection. The positive rate of *Legionella* culture was 3.32% (7/211). All isolated *Legionella* strains were *L. pneumophila* serogroup 1.

All 11 urine antigen--positive patients were male, 23--76 years of age (average 56 years) ([Table](#T1){ref-type="table"}). They resided in 7 cities, and most (9/11) cases were observed in summer (in China, July--September). All were hospitalized; length of hospitalization ranged from 7 to 93 days. Six were admitted to an intensive care unit. The case-fatality rate was 18.2% (2/11) after antimicrobial and supportive therapies.

###### Characteristics of 11 Legionnaires' disease patients, China\*

  Patient ID   Age, y   Date of diagnosis   Onset city   Underlying illness   Length of hospitalization, d   ICU admission   Outcome     SBT type of isolates
  ------------ -------- ------------------- ------------ -------------------- ------------------------------ --------------- ----------- ----------------------
  1            45       2014 Sep            Shenyang     None                 15                             Yes             Recovered   ST2344
  2            70       2014 Aug            Beijing      None                 93                             Yes             Recovered   ST59
  3            53       2015 Aug            Hefei        None                 18                             No              Recovered   ST2369
  4            63       2016 Jan            Jinan        None                 16                             No              Recovered   ST42
  5            67       2016 Aug            Haikou       Diabetes             21                             No              Recovered   ST742
  6            23       2016 Jul            Beijing      AIDS                 7                              Yes             Died        ST2366
  7            53       2016 Sep            Shanghai     None                 14                             Yes             Recovered   ST2368
  8            58       2016 May            Lishui       None                 8                              No              Recovered   NS
  9            49       2014 Jul            Shenyang     Cirrhosis            14                             Yes             Died        NS
  10           76       2015 Jul            Beijing      None                 17                             Yes             Recovered   NS
  11           59       2016 Sep            Jinan        None                 22                             No              Recovered   NS

\*All patients were male. ICU, intensive care unit; ID, identification; NS, no strain isolated; SBT, sequence-based typing; ST, sequence type.

We performed antimicrobial susceptibility testing using E-test strips (bioMérieux, <https://www.biomerieux.com>). According to the epidemiologic cutoff values of the European Committee on Antimicrobial Susceptibility Testing ([@R4]) or as determined by a previous study ([@R5]), all 7 strains were susceptible to fluoroquinolones, macrolides, and rifampin but not to cefuroxime ([Appendix](#SD1){ref-type="local-data"} Table 1).

We subtyped the 7 strains using pulsed-field gel electrophoresis ([@R6]) and sequence-based typing (SBT) ([@R7]). All 7 strains were identified as different pulsed-field gel electrophoresis and SBT types ([Appendix](#SD1){ref-type="local-data"} Figure 3). Submission to the European Working Group on *Legionella* Infections *L. pneumophila* SBT database (<http://www.ewgli.org>) identified 4 profiles as new; these profiles were assigned new sequence types (STs) (ST2344, ST2366, ST2368, and ST2369). Querying the European Working Group on *Legionella* Infections database showed that 2 STs (ST42 and ST59) contained strains that are distributed worldwide ([Appendix](#SD1){ref-type="local-data"} Table 2). We also tested the 7 strains for their intracellular growth ability using previously described methods ([@R8]), and all showed high intracellular growth in J774 cells, suggesting that these strains are pathogenic ([Appendix](#SD1){ref-type="local-data"} Figure 4).

Many Legionnaires' disease cases are reported worldwide, including hundreds in the United States and Europe each year (*9*,[@R9]). However, no data are available on the prevalence of Legionnaires' disease in China. In China, no *Legionella* urine antigen test reagent has been approved for clinical diagnosis and few hospitals conduct *Legionella* culture, so in clinical laboratories, Legionnaires' disease is difficult to detect; therefore, diagnosis is based mainly on signs and symptoms. Legionnaires' disease is usually diagnosed as unexplained pneumonia.

The results of this study showed that *L. pneumophila* is an important pathogen for pneumonia patients in China, and current diagnostic methods in China may misdiagnose or overlook it. We suggest establishment of a routine monitoring reporting system to investigate the prevalence and epidemiology of Legionnaires' disease in China.

###### Appendix

Additional information from a study of Legionnaires' disease surveillance, China, 2014--2016.
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